This first installment of a two-part article on new antiretroviral drugs in development provides information on seven new protease inhibitors (PIs). The results of in vitro and in vivo trials are provided. Researchers hope these drugs will be more potent and effective, have favorable resistance profiles, and be better tolerated by patients. Featured PIs include ABT 378, tipranavir, and DMP 450.
|Original language||English (US)|
|Number of pages||3|
|Journal||AIDS clinical care|
|State||Published - Jan 1 1999|